Bli medlem
Bli medlem

Du är här



The Annual General Meeting of XVIVO Perfusion AB (publ) will take
place on Tuesday April 29, 2014, at 5 p.m. in the company's premises
at Mässans gata 10 in Gothenburg. Notice of attendance at the Annual
General Meeting shall be given no later than Wednesday, April 23,

Shareholders wishing to participate at the Annual General Meeting
shall notify the company by mail to XVIVO Perfusion AB (publ), Box
53015, SE-400 14 Gothenburg, Sweden, Att: Catrin Olsson, by phone +46
31-788 21 53, by fax +46 31-788 21 69 or by e-mail Name/business name, personal
identification number/ company registration number (or the
equivalent), address, telephone number, number of shares, details of
any advisors and where appropriate details of a representative or
proxy must be stated in the notification. A proxy form in Swedish for
shareholders wishing to be represented by proxy will be found on

Shareholders that have their shares registered in the name of a
nominee must temporarily record their shares in the share register
kept by Euroclear Sweden AB in their own names to be able to attend
the General Meeting. Such registration must be carried out no later
than Wednesday, April 23, 2014.

Attachment: Full notice (in Swedish)

March 28, 2014
XVIVO Perfusion AB (publ)
The Board

Queries should be addressed to:

Fredrik Mattsson, Chairman of the Board, phone +46 8-614 00 20
Christoffer Rosenblad, CFO, phone +46 31-788 21 59

Xvivo Perfusion is required to publish the information in this press
release in accordance with the Swedish Securities Market Act and/or
the Financial Instruments Trading Act. The information was submitted
for publication on March 28, 2014 at 8:30 a.m.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in the USA. The XVIVO share is listed on NASDAQ OMX First North and
has the ticker symbol XVIVO. More information can be found on the
website The Certified Adviser is Redeye,


XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.